Is Rezum water‑vapor thermal therapy indicated for a patient with mild benign prostatic hyperplasia (BPH) and prostatomegaly who has a pre‑void urine volume of 401 mL and a post‑void residual urine volume of 207 mL?

Rezūm is NOT indicated for this patient with mild prostatomegaly and significant post-void residual urine of 207 mL

Based on current evidence, this patient should first undergo medical therapy (alpha-blocker ± 5-ARI) rather than proceeding directly to Rezūm, as the elevated PVR (207 mL) suggests bladder dysfunction that may predict less favorable response to minimally invasive procedures.

Clinical Reasoning

Why Rezūm is Premature Here

The 2019 AUA Guideline 1 establishes that clinicians should perform a post-void residual assessment prior to surgical intervention for LUTS/BPH as a clinical principle. Your patient's PVR of 207 mL falls into a concerning range that warrants careful consideration.

The 2003 AUA Guidelines 2 specifically note that:

• Large PVR volumes (referenced as 350 mL, but noting concern at 200-300 mL range) may indicate bladder dysfunction and predict a slightly less favorable response to treatment
• The safety of noninvasive therapy has not been well-documented in patients with residual urine in the 200-300 mL range
• No level of residual urine mandates invasive therapy by itself, but it does signal potential bladder decompensation

The Appropriate Treatment Pathway

Step 1: Medical Therapy First

For this patient with "mild prostatomegaly" and bothersome symptoms (evidenced by the significant PVR), the 2021 AUA Guideline 3 recommends:

• Start with an alpha-blocker (alfuzosin, doxazosin, tamsulosin, or terazosin) for rapid symptom relief
• If prostate volume >30 cc, consider adding a 5-alpha reductase inhibitor (finasteride or dutasteride)
• Re-evaluate at 4-12 weeks with IPSS scoring and repeat PVR measurement

Step 2: Assess Response

The elevated PVR of 207 mL (52% of pre-void volume) suggests either:

• Bladder outlet obstruction from BPH
• Detrusor underactivity/bladder dysfunction
• Combination of both

Medical therapy can help differentiate these. If PVR improves significantly with alpha-blocker therapy, this confirms obstruction as the primary issue. If PVR remains elevated despite medical therapy, this suggests bladder dysfunction that would predict poor response to any BPH procedure 2.

When Rezūm Would Be Appropriate

Rezūm could be considered after medical therapy trial if:

1. Inadequate symptom relief despite 3-6 months of optimized medical therapy
2. PVR improves with medical therapy (suggesting reversible obstruction rather than fixed bladder dysfunction)
3. Patient desires to discontinue medications due to side effects or preference

Recent evidence 4 shows Rezūm can work in patients with various LUTS severities, but notably:

• Patients with moderate-to-severe LUTS saw significant improvements starting at 1 month
• Patients with mild LUTS actually experienced temporary worsening at 1 month before returning to baseline at 3 months
• The primary benefit in mild LUTS patients was medication discontinuation (80% at 12 months) and nocturia improvement

Critical Caveats About PVR and Rezūm

While newer studies 5, 6 demonstrate Rezūm can work in larger prostates (≥80 cc) with good PVR reduction (68.8% improvement in large prostates), these studies don't specifically address patients with baseline elevated PVR as a predictor of outcome. The 2003 AUA Guidelines 2 remain relevant: large PVRs may herald disease progression and predict less favorable treatment response.

The concern is bladder decompensation: A PVR of 207 mL in a patient with "mild prostatomegaly" suggests the bladder may already be failing to empty effectively. Proceeding directly to Rezūm without first attempting medical therapy risks:

• Poor symptomatic improvement if bladder dysfunction is the primary issue
• Potential for acute urinary retention post-procedure
• Unnecessary invasive intervention when medical therapy might suffice

Practical Algorithm

1. Obtain IPSS score to quantify symptom severity and bother
2. Start alpha-blocker (e.g., tamsulosin 0.4 mg daily)
3. Measure prostate volume via ultrasound or DRE estimation
4. If prostate >30 cc, add 5-ARI (finasteride 5 mg or dutasteride 0.5 mg daily)
5. Re-evaluate at 6-12 weeks: Repeat IPSS, PVR, and uroflowmetry
6. If PVR decreases and symptoms improve: Continue medical therapy
7. If inadequate response or intolerable side effects: Consider Rezūm or other surgical options
8. If PVR remains >200 mL despite medical therapy: Consider urodynamic studies before proceeding with any invasive therapy 2

The 2019 AUA Guideline 1 supports considering uroflowmetry and potentially pressure-flow studies prior to surgical intervention, particularly when baseline parameters suggest bladder dysfunction.